- Home
- FOLD vs WLYB Comparison
FOLD vs WLYB Comparison
Compare FOLD & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- WLYB
- Stock Information
- Founded
- FOLD 2002
- WLYB 1807
- Country
- FOLD United States
- WLYB United States
- Employees
- FOLD N/A
- WLYB N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- WLYB Books
- Sector
- FOLD Health Care
- WLYB Consumer Discretionary
- Exchange
- FOLD Nasdaq
- WLYB Nasdaq
- Market Cap
- FOLD 2.9B
- WLYB 2.3B
- IPO Year
- FOLD 2007
- WLYB N/A
- Fundamental
- Price
- FOLD $6.16
- WLYB $38.55
- Analyst Decision
- FOLD Buy
- WLYB
- Analyst Count
- FOLD 10
- WLYB 0
- Target Price
- FOLD $16.22
- WLYB N/A
- AVG Volume (30 Days)
- FOLD 5.0M
- WLYB 61.0
- Earning Date
- FOLD 05-01-2025
- WLYB 06-17-2025
- Dividend Yield
- FOLD N/A
- WLYB 3.59%
- EPS Growth
- FOLD N/A
- WLYB N/A
- EPS
- FOLD N/A
- WLYB 0.75
- Revenue
- FOLD $543,141,000.00
- WLYB $1,703,491,000.00
- Revenue This Year
- FOLD $19.85
- WLYB N/A
- Revenue Next Year
- FOLD $23.50
- WLYB $1.13
- P/E Ratio
- FOLD N/A
- WLYB $51.06
- Revenue Growth
- FOLD 28.25
- WLYB N/A
- 52 Week Low
- FOLD $5.81
- WLYB $35.68
- 52 Week High
- FOLD $12.65
- WLYB $52.90
- Technical
- Relative Strength Index (RSI)
- FOLD 41.91
- WLYB 8.42
- Support Level
- FOLD $6.03
- WLYB $39.54
- Resistance Level
- FOLD $6.37
- WLYB $44.15
- Average True Range (ATR)
- FOLD 0.24
- WLYB 0.03
- MACD
- FOLD 0.04
- WLYB -0.50
- Stochastic Oscillator
- FOLD 41.67
- WLYB 0.00
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.